Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9161926 | ALMIRALL | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
US9517219 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
US11273132 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Sep 10, 2022 |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 24 February, 2016
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7875630 | ALMIRALL | Process salts compositions and use |
Feb, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(11 months from now) |
Drugs and Companies using RETAPAMULIN ingredient
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: OINTMENT;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8980890 | ALMIRALL | Compositions and methods of treating cell proliferation disorders |
Dec, 2025
(2 years from now) | |
US8236799 | ALMIRALL | Biaryl compositions and methods for modulating a kinase cascade |
Dec, 2025
(2 years from now) | |
US7300931 | ALMIRALL | Compositions for treating cell proliferation disorders |
Feb, 2026
(2 years from now) | |
US7851470 | ALMIRALL | Composition and methods for modulating a kinase cascade |
Feb, 2029
(5 years from now) | |
US10669236 | ALMIRALL | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
Sep, 2038
(14 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(4 years from now) | |
US11497750 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(14 years from now) | |
US10617693 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(14 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 14, 2025 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 2024-12-14
Market Authorisation Date: 14 December, 2020
Treatment: Topical treatment of actinic keratosis of the face or scalp
Dosage: OINTMENT;TOPICAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8318706 | ALMIRALL | Substituted tetracycline compounds |
May, 2031
(7 years from now) | |
US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9481639 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Aug, 2028
(4 years from now) | |
US8513223 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Dec, 2029
(6 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 1, 2023 |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
NCE-1 date: 2022-10-01
Market Authorisation Date: 01 October, 2018
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9492384 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 11 months from now) | |
US8962000 | ALMIRALL | Microemulsion and sub-micron emulsion process and compositions |
Aug, 2025
(1 year, 11 months from now) | |
US8460641 | ALMIRALL | Microemulsion process and composition |
Aug, 2027
(3 years from now) |
Drugs and Companies using DESONIDE ingredient
Market Authorisation Date: 19 September, 2006
Treatment: Treatment of atopic dermatitis
Dosage: AEROSOL, FOAM;TOPICAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic